Related Experiment Videos
The next frontier: AI, multi-omics, and predictive models for weight gain in HIV
1Division of Infectious Diseases, Department of Medicine, Vanderbilt Health, Nashville, Tennessee, USA.
Current Opinion in HIV and AIDS
|August 13, 2026
Summary
People with HIV (PWH) are gaining excess weight and obesity after starting antiretroviral therapy. Machine learning and multi-omics show promise for predicting weight gain and improving health outcomes in PWH.
Area of Science:
- Biomedical research
- Data science
- Genomics
Background:
- People with HIV (PWH) face increasing rates of excess weight gain and obesity following antiretroviral therapy initiation.
- Individual weight gain varies significantly and is poorly predicted by clinical factors alone.
- Obesity in PWH has a complex pathophysiology influenced by biological and environmental interactions.
Purpose of the Study:
- To review emerging machine learning and multi-omics methods for understanding and predicting weight gain in PWH.
- To explore the challenges and future directions in this research area.
Main Methods:
- Review of recent studies utilizing machine learning and multi-omics approaches.
- Analysis of data to identify biological and environmental factors contributing to weight gain.
Main Results:
- Few studies have applied omics or machine learning to model weight gain trajectories in PWH.
- Existing studies demonstrate the potential and difficulties of using multi-omics and machine learning for weight gain prediction.
- These advanced methods are crucial for understanding complex disease pathways.
Conclusions:
- Machine learning and multi-omics are accelerating the understanding of human health and disease.
- These tools can define the biology and predictors of weight gain in PWH.
- Improved prediction and targeted interventions can enhance health outcomes for PWH.
Related Concept Videos
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...